BD’s Rotarex Atherectomy System is developed to remove and aspirate varying lesion morphologies. Credit: SKreutz / commons.wikimedia.org.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Becton, Dickinson and Company’s (BD) Rotarex Atherectomy System expanded indications.

A rotational excisional device, the Rotarex Atherectomy System is designed to remove and aspirate varying lesion morphologies, including plaque and thrombus, in peripheral arteries.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It has already secured clearance for use in native arterial vessels.

Now, the device has expanded indications for treatments inside peripheral arteries that are fitted with stent grafts, stents, and native or artificial bypasses.

The Rotarex Atherectomy System has a small plug-and-play capital component and reusable handle, which makes it easy to use and simple to set up. It does not require infusions or catheter cleanout.

It is claimed to be the first and only atherectomy and thrombectomy device which is indicated to treat in-stent restenosis in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The FDA clearance of the device’s expanded indication for treatments within peripheral arteries comes after more than ten years of real-world clinical experience.

The clearance will allow physicians to use the Rotarex Atherectomy System to address some of their most challenging peripheral arterial disease (PAD) lesions.

BD peripheral intervention worldwide president Paddy O’Brien said: “The additional indications provide physicians a one-of-a-kind, ideal solution for treating complex lesions associated with PAD and further demonstrates our responsibility as an industry to develop innovative technologies to help with the fight against PAD.”

The device’s unique mechanism enables the simultaneous treatment of plaque and thrombus.

In June, the FDA expanded its 510(k) clearance for the BD PeritX Peritoneal Catheter System to drain symptomatic, recurrent, non-malignant ascites.